UCB

Canaccord Genuity has Advised UCB on the divestment of the rights to Nootropil® and Atarax® to Advanz Pharma

Canaccord Genuity is pleased to announce it has advised UCB, a global biopharmaceutical company, on the divestment of the rights to Nootropil® and Atarax® to ADVANZ PHARMA, a UK headquartered global pharmaceutical company, for Europe and selected countries in LATAM and APAC.